Categories Health Care, Markets

Gilead’s credibility takes a hit on massive NASH-drug failure, rivals jump

Shares of Gilead Sciences (GILD) have tumbled 20% in the past 52 weeks on numerous reasons including weaker-than-expected quarterly results and a slowdown in the HIV segment. Gilead bulls have been betting on its ongoing research on nonalcoholic steatohepatitis (NASH), a liver disease, to boost topline growth in the future.

However, these hopes and the biotechnology company’s credibility as a whole took a hit on Tuesday when it said it failed to meet the primary endpoint of its most advanced NASH candidate, selonsertib, in a Phase 3 trial.

Photo by Drew Hays on Unsplash

Compared to placebo, selonsertib failed to elicit any significant improvement in the patient’s health status, even on a high dosage. The phase 3 trial was done on about 900 patients for 48 days.

GILD shares fell 4.3% during regular trading hours on Tuesday. Meanwhile, rivals Viking Therapeutics (VKTX) and Madrigal Pharmaceuticals (MDGL) – who are also in the race to bring out a NASH drug – saw their stock jump 6% and 3.6% respectively on the news.

The clinical trial results were so weak that Gilead may pull the plug on the drug’s development altogether. There are other investigational NASH drugs in Gilead’s pipeline, but these will take time to reach the market, in case they come out of the trials successfully. And there is a likelihood that one of the rivals reach the market first.

Also read: Gilead names Daniel O’Day as Chairman and CEO

With Gilead losing out, Intercept Pharmaceuticals (ICPT) is currently at the forefront in the race, with its Phase 3 clinical trial expected this quarter-end.

Last week, Gilead said it swung to a profit in the fourth quarter from a loss last year, helped by a plunge in income taxes provision. The top line exceeded analysts’ expectations while the bottom line missed consensus estimates. The biotechnology company also guided full-year 2019 product sales in line with the street’s view.

 

We’re on Apple News! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

AVGO Earnings: All you need to know about Broadcom Q1 2021 earnings results

Broadcom Limited (NASDAQ: AVGO) reported first quarter 2021 earnings results today. Total revenue increased 14% year-over-year to $6.65 billion. GAAP net income was $1.3 billion, or $3.05 per share, compared

Infographic: Costco (COST) Q2 2021 sales up 15%; earnings miss

Retail giant Costco Wholesale Corporation (NASDAQ: COST) reported higher earnings and revenues for the second quarter of 2021. Earnings missed analysts’ expectations, while sales beat. Net profit was $951 million

Will shifting to as-a-service model help Hewlett Packard in emerging stronger from COVID?

With the corporate world rapidly shifting to cloud-native computing after the virus outbreak changed work culture and the way businesses operate, technology providers are aggressively innovating their offerings. Hewlett Packard

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top